QQ客服 官方微博 反馈留言

	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
	Yi, Zongbi; Ma, Fei; Liu, Binliang; Guan, Xiuwen; Li, Lixi; Li, Chunxiao; Qian, Haili; Xu, Binghe
	2019
卷号	19期号:1页码:442
关键词	Biomarkers Breast neoplasms ctDNA Everolimus
ISSN号	1471-2407
DOI	10.1186/s12885-019-5668-3
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6341648
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yi, Zongbi,Ma, Fei,Liu, Binliang,et al. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study[J],2019,19(1):442.
APA	Yi, Zongbi.,Ma, Fei.,Liu, Binliang.,Guan, Xiuwen.,Li, Lixi.,...&Xu, Binghe.(2019).Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.,19(1),442.
MLA	Yi, Zongbi,et al."Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study".19.1(2019):442.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。